$-0.89 EPS Expected for Aclaris Therapeutics Inc (ACRS)

October 7, 2017 - By Max Morgan

 $ 0.89 EPS Expected for Aclaris Therapeutics Inc (ACRS)

Wall Street await Aclaris Therapeutics Inc (NASDAQ:ACRS) to release earnings on November, 2. Analysts forecast earnings per share of $-0.89, down exactly $0.39 or 78.00 % from 2014’s $-0.5 EPS. After posting $-0.56 EPS for the previous quarter, Aclaris Therapeutics Inc’s analysts now forecast 58.93 % negative EPS growth. The stock increased 1.47% or $0.4 on October 6, reaching $27.61. About 305,732 shares traded or 8.57% up from the average. Aclaris Therapeutics Inc (NASDAQ:ACRS) has risen 25.57% since October 8, 2016 and is uptrending. It has outperformed by 8.87% the S&P500.

Aclaris Therapeutics Inc (NASDAQ:ACRS) Ratings Coverage

Among 6 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Aclaris Therapeutics had 13 analyst reports since November 2, 2015 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Friday, July 28. The stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) earned “Outperform” rating by Leerink Swann on Tuesday, November 29. The firm has “Buy” rating given on Monday, September 19 by Jefferies. The stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) earned “Buy” rating by Jefferies on Friday, August 12. The rating was initiated by William Blair with “Outperform” on Monday, November 2. Jefferies maintained it with “Buy” rating and $36.0 target in Thursday, August 31 report. The stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) has “Market Perform” rating given on Friday, September 30 by JMP Securities. The rating was maintained by Jefferies on Monday, June 26 with “Buy”. Jefferies initiated Aclaris Therapeutics Inc (NASDAQ:ACRS) on Monday, November 2 with “Buy” rating. Guggenheim initiated the shares of ACRS in report on Friday, June 10 with “Buy” rating.

Aclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The company has market cap of $840.38 million. The Firm is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. It currently has negative earnings. The Firm is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

More notable recent Aclaris Therapeutics Inc (NASDAQ:ACRS) news were published by: Nasdaq.com which released: “Aclaris Therapeutics Acquires Confluence Life Sciences, Inc.” on August 08, 2017, also Globenewswire.com with their article: “Aclaris Therapeutics Reports First Quarter 2017 Financial Results” published on May 09, 2017, Seekingalpha.com published: “Aclaris: Bright Future Ahead With Dermatology And Alopecia Treatments” on July 18, 2017. More interesting news about Aclaris Therapeutics Inc (NASDAQ:ACRS) were released by: Globenewswire.com and their article: “Aclaris Therapeutics Announces Notice of Allowance for a US Patent Application …” published on April 26, 2017 as well as Fool.com‘s news article titled: “Why Aclaris Therapeutics, Inc. Stock Is Down Today” with publication date: November 17, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com